ArticleBreast cancer research : BCR2025

Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study.

Sanna Steen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.